<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nuclear factor-kappaB (NF-κB) p50/RelA is a key molecule with a dual effect in the progression of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In harmful <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but not in preconditioning insult, neurotoxic activation of p50/RelA is characterized by RelA-specific acetylation at Lys310 (K310) and deacetylation at other Lys residues </plain></SENT>
<SENT sid="2" pm="."><plain>The derangement of RelA acetylation is associated with activation of <z:chebi fb="3" ids="33173">Bim</z:chebi> promoter </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: With the aim of producing neuroprotection by correcting altered acetylation of RelA in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, we combined the pharmacological inhibition of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) 1-3, the enzymes known to reduce global RelA acetylation, and the activation of sirtuin 1, endowed with a specific deacetylase activity on the K310 residue of RelA </plain></SENT>
<SENT sid="4" pm="."><plain>To afford this aim, we tested the clinically used HDAC 1-3 inhibitor entinostat (MS-275) and the sirtuin 1 activator <z:chebi fb="0" ids="27881">resveratrol</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: We used the mouse model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and primary cortical neurons exposed to oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The combined use of MS-275 and <z:chebi fb="0" ids="27881">resveratrol</z:chebi>, by restoring <z:mpath ids='MPATH_458'>normal</z:mpath> RelA acetylation, elicited a synergistic neuroprotection in neurons exposed to OGD </plain></SENT>
<SENT sid="7" pm="."><plain>This effect correlated with MS-275 capability to increase total RelA acetylation and <z:chebi fb="0" ids="27881">resveratrol</z:chebi> capability to reduce RelA K310 acetylation through the activation of an <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase-sirtuin 1 pathway </plain></SENT>
<SENT sid="8" pm="."><plain>The synergistic treatment reproduced the acetylation state of RelA peculiar of preconditioning <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Neurons exposed to the combined drugs totally recovered the optimal <z:chebi fb="0" ids="15358">histone</z:chebi> H3 acetylation </plain></SENT>
<SENT sid="10" pm="."><plain>Neuroprotection was reproduced in mice subjected to MCAO and treated with MS-275 (20μg/kg and 200μg/kg) or <z:chebi fb="0" ids="27881">resveratrol</z:chebi> (6800μg/kg) individually </plain></SENT>
<SENT sid="11" pm="."><plain>However, the administration of lowest doses of MS-275 (2μg/kg) and <z:chebi fb="0" ids="27881">resveratrol</z:chebi> (68μg/kg) synergistically reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological deficits </plain></SENT>
<SENT sid="12" pm="."><plain>Importantly, the treatment was effective even when administered 7h after the <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Chromatin immunoprecipitation analysis of cortices harvested from treated mice showed that the RelA binding and <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation increased at the Bcl-x(L) promoter and decreased at the <z:chebi fb="3" ids="33173">Bim</z:chebi> promoter </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Our study reveals that epigenetic therapy shaping acetylation of both RelA and <z:chebi fb="0" ids="15358">histones</z:chebi> may be a promising strategy to limit post-ischemic injury with an extended therapeutic window </plain></SENT>
</text></document>